|drug3139||Soluble Urokinase Plasminogen Activator Receptor Wiki||1.00|
There is one clinical trial.
The goal of this project is to rapidly screen promising agents, in the setting of an adaptive platform trial, for treatment of critically ill COVID-19 patients. In this phase 2 platform design, agents will be identified with a signal suggesting a big impact on reducing mortality and the need for, as well as duration, of mechanical ventilation.
Description: Time to achieve durable change in COVID-19 to ordinal level 4 or less for at least 48 hoursMeasure: Identify agents that will result in substantial improvements to the clinical condition of participants with COVID-19 Time: Up to 28 days
Description: % of COVID-19 level 5 who never progress to COVID-19 level 6/7Measure: Improvement in disease severity Time: Up to 60 days
Description: Ventilator-free DaysMeasure: Health care utilization Time: Up to 60 days
Description: Total grade 3 or higher AEs by arm and total number of patients with grade 3 or higher AEs by arm. ● Total grade 3 or higher AEs of special interest by arm and total number of patients with grade 3 or higher AEs of special interest by arms (based upon lab assessments)Measure: Frequency of serious AEs Time: Up to 60 days
Description: Mortality at 28 days after study enrollmentMeasure: Mortality Time: Up to 28 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports